NCT02207556View on ClinicalTrials.gov

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

May 19, 2020

Conditions
Primary Systemic Amyloidosis
Interventions
DRUG

Doxycycline

"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."

Trial Locations (1)

53226

Froedtert & Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Medical College of Wisconsin

OTHER

NCT02207556 - Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial | Biotech Hunter | Biotech Hunter